Winter 2015 Magic Red Cathepsin Kit Citations

Our Magic Red products have been cited in two journals this winter. In the first article, ICT’S Magic Red Cathepsin L Assay was used to measure cathepsin L activation in human aortic endothelial cells. Weikel KA, Cacicedo JM, Ruderman NB, Ido Y. Glucose and palmitate uncouple AMPK from autophagy in human aortic endothelial cells. 2015. J. Cell Physio. doi:10.1152/ajpcell.00265.2014  [Abstract]… Read more »

Magic Red Cathepsin B Kits Cited in Research on Phagosome and Lysosome Maturation

Two articles have recently been published in the Journal of Cell Science and mBio, an open access journal published by the American Society for Microbiology, citing our Magic Red Cathepsin B Assay Kits (ICT# 937, 938). Li, K, Yang, L, Zhang, C, Niu, Y, Wei, L, Liu, J. (2014). HPS6 interacts with dynactin p150Glued to mediate retrograde… Read more »

Studies of Post-Infection Inflammatory Response Cite FLICA Caspase-1 Assays

Our FLICA® Caspase-1 Assay Kits have recently been cited in two research publications involving studies of the inflammatory response after microbial infection.

The first study, authored by researchers at the Utrecht University Department of Infectious Diseases and Immunology, studied a pathogen that causes foodborne disease and gastroenteritis, Campylobacter jejuni.

We’re CELL-ebrating our 20th Anniversary

20 Years of Solutions

ImmunoChemistry Technologies would like to express our gratitude to our customers, partners, and collaborators for their support over the past two decades. Cheers! 

Founded in 1994, ImmunoChemistry Technologies has grown to become a strong and growing biotechnology company with a loyal and ever-expanding customer base working in biomedical research labs all over the world.

FLICA Caspase Assays Cited in Anticancer Screening Study of Imidazolium Compounds

Research on anticancer potential of imidazolium-based ionic salts reveals four compounds with nanomolar toxic potency against human cancer cell lines

Congratulations to our customers at the Frederick National Laboratory for Cancer Research and the Universidad Metropolitana School of Environmental Affairs for publishing their recent study of the effects of imidazolium-based compounds on 60 human cancer cell lines in the September 2014 issue of MedChemComm.

ICT Owners Complete Ice Bucket Challenge

Lee and Hed douse themselves in ice water to bring awareness to ALS and medical research, challenge industry colleagues

August 27, 2014 – BLOOMINGTON, Minn. — Challenge accepted! Dr. Brian Lee and Ms. Sally Hed, co-owners of ImmunoChemistry Technologies, were nominated to complete the ALS Ice Bucket Challenge. They accepted the challenge on this sunny day in August and made a donation to the ALS Association.